Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Gracell, a CAR-T Company, to be Acquired by AstraZeneca for $1.2 Billion

publication date: Dec 26, 2023

Gracell Biotech, a Suzhou-San Diego cell therapy company, will be acquired by AstraZeneca in a deal worth up to $1.2 billion. AstraZeneca will acquire at least one clinical stage CAR-T therapy plus Gracell’s FasTCAR next-day manufacturing technology. Gracell shareholders will receive $10.00 per ADS ($2.00 per ordinary share) in cash at closing, plus a non-tradable contingent value right for up to $1.50 per ADS ($0.30 per ordinary share) for a single regulatory milestone. The acquisition is priced at an 86% premium to Gracell’s previous closing market price. More details....

Stock Symbol: (NSDQ: GRCL)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital